Email david.wu@nus.edu.sg

Dr. Wu is a seasoned industry leader and currently the Regional Director of Real-World Evidence (RWE) & Health Economics (HE) for Market Access (Asia Pacific) at Johnson & Johnson Innovative Medicine. He leads the development and execution of cross-functional RWE and HE strategies across all therapeutic areas and product life cycle to support market access, including HTA submissions and successful commercialization. His work involves close collaboration with global and regional teams across market access, commercial, medical affairs, and epidemiology to generate impactful evidence that informs policy, accelerates patient access, and substantiates the value of innovative therapies.

Besides, Dr. Wu has also collaborated with leading global institutions, including the World Health Organization, U.S. National Institutes of Health, USAID, and Taiwan’s Centers for Disease Control. He has served as an advisor to the Ministries of Health in Malaysia and the Philippines, and has supported numerous pharmaceutical companies in advancing health economics and outcomes research (HEOR) to inform policy, optimize resource allocation, and improve patient access to innovative therapies.

Dr. Wu has keen research interests in RWE analytics, economic evaluation, evidence synthesis, and advanced statistical methodologies including causal inference, AI/machine learning, Bayesian approaches for censored cost-effectiveness data, survival curve extrapolation, and surrogate endpoint validation—aimed at addressing complex methodological challenges in healthcare decision-making and policy. He has co-authored over 100 peer-reviewed publications and abstracts in leading journals such as Value in Health, PharmacoEconomics, BMC Cancer, Vaccine, and Infectious Diseases & Therapy. He also serves as a statistical adviser and editorial board member for several international journals.

A passionate educator, Dr. Wu has taught HEOR courses at ISPOR Asia Pacific Conferences and delivered invited trainings for ISPOR regional chapters. He is an active member of ISPOR, the ISPOR Taiwan and Singapore Chapters, and the Society for Medical Decision Making.

• NUS Saw Swee Hock School of Public Health (Adjunct)
• Regional Director of RWE & Health Economics, Market Access (Asia Pacific), Johnson & Johnson Innovative Medicine (Primary)

• Real world evidence
• Epidemiology
• AI/machine learning
• Economic evaluation / economic modeling
• Evidence synthesis
• Statistical methodologies in RWE/HEOR/epidemiology
• Comparative effectiveness research
• Clinical outcomes assessment methods

• SPH5405 (Introduction to Health Services Research)
• SPH5420 (Evidence synthesis for health technology assessment)
• MCI5009 (Health Services Research Methods for Clinicians)

• PhD in Biostatistics, National Yang Ming Chiao Tung University, Institute of Public Health, Taiwan
• M.Com in Statistics, Department of Statistics, College of Commerce, National Cheng Chi University, Taiwan
• BSc in Mathematics, Department of Mathematics, Soochow University, Taiwan

• Regional Director, Real World Evidence, Market Access (Asia Pacific), Johnson & Johnson Innovative Medicine
• Adjunct Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore
• Lead Specialist, Economic Modeling, Agency for Care Effectiveness, Ministry of Health, Singapore
• Adjunct Senior Lecturer, Monash University Malaysia
• Senior Lecturer, Monash University Malaysia
• Postgraduate Research Fellow, Chang Gung University, Taiwan

• Editor, Journal of Medical Economics
• Associate editor and statistical adviser, Archive of Pharmacy Practice
• Statistical editor, Journal of Clinical Practice and Health Sciences
• Reviewer editor, Frontiers in Pharmacology – Pharmaceutical Medicine and Outcomes Research
• ISPOR Asia Pacific Short Course Committee

• Wu DB, Tsai YW, Wen YW. (2012). Bayesian cost-effectiveness analysis for censored data – an application to antiplatelet therapy. Journal of Medical Economics 15(3):434-43.
• Wu DB, Chaiyakunapruk N, Beutels P. (2015). Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006-2014). Vaccine 33(14):1633-1658.
• Chong HY, Chaiyakunapruk N, Teoh SL, Wu DB, Kotirum S, Chiou CF. (2016). Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment 12:357-73.
• Wu DB*, Lee KK, Roberts C, Lee VWY, Hong LW. (2016). Cost-effectiveness analysis of 13-and 10-valent pneumococcal conjugate vaccines for infants in Malaysia and Hong Kong. (*: Corresponding author) Human Vaccines & Immunotherapeutics 12(2):403-16.
• Wu DB, Chaiyakunapruk N, Pratoomsoot C, Lee KKC, Chong HY, Nelson R, Smith PF, Kirkpatrick C, Kamal MA, Nieforth K, Dall G, Toovey S, Kong DCM, Kamauu A, Nelson R, Rayner CR. (2018). Cost-utility analysis of antiviral use under pandemic influenza using a novel approach – linking pharmacology, epidemiology and heath economics. Epidemiology and Infection 146(4):496-507. 15:1-12.
• Tan PT, Aziz Abdul MI, Pearce F, Wu DB*, Ng KH*. (2018). Erlotinib, gefitinib and afatinib for the first-line treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. (*: Co-corresponding author) BMC Cancer 18: 352
• Tan G, Aziz MI, Wu DB, Liang L, Tan PT, Ng K. (2018). Long-acting muscarinic antagonist monotherapy and combination therapy with long-acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: A network meta-analysis. International Journal of COPD 13:3203-3231
• Choon JWY, Wu DB*, Lo TL, Chung WS, Chui EMC, Tomlinson B, Lee VWY, Lee SC, Lee KKC. (2019). Real-world evidence of improved healthcare utilization in patients with recent onset schizophrenia after paliperidone palmitate once-monthly treatment in Hong Kong. (*: Corresponding author) Journal of Medical Economics, 22(3):273-279.
• Liu JY, Yu Z, Wu B, Wang S, Wu DB*, You RX. Cost-Effectiveness of testing for NS5A resistance to optimize treatment of elbasvir/grazoprevir for chronic hepatitis C in China. (2021) (*: Corresponding author). Frontiers in Pharmacology, section Drugs Outcomes Research and Policies Oct 15;12:717504. doi: 10.3389/fphar.2021.717504. eCollection 2021.
• Tsai IC, Yu DY, Wu DB*. Association between second progression-free survival and overall survival in metastatic castration-resistant prostate cancer in Japan: An analysis using national MDV claims database (*: Corresponding author). (2022) Curr Med Res Opin; 38(8):1351-1359. doi: 10.1080/03007995.2022.2096353.
• Wattanakamolkul K, Nakayama Y, Sbarigia U, Lim KH, Lacuesta VC, Tsai IC, Yu DY, Wu DB*. Epidemiology and treatment patterns of chronic hepatitis B virus in Japan: A nationwide population-based study using national MDV database. (2023) (*: Corresponding author). Infectious Diseases & Therapy https://doi.org/10.1007/s40121-023-00795-0
• Atsumi T, Tan JY, Chiang APC, Yu DY, Makanji Y, Wu DB*, Casorso J, Kouhkamari M, Lim S. Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus–pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan. (*: Corresponding author). (2023) Modern Rheumatology https://doi.org/10.1093/mr/road090
• Tan CK, Wu DB, Tan SYJ, Lin YY, Imran SS, Wee XT, Tan DSY. Validating the prognostic utility of the ABCD-GENE score in Asian patients with acute coronary syndrome patients on clopidogrel. (2023) European Cardiology Review European Cardiology Review DOI:https://doi.org/10.15420/ecr.2023.27
• Omura J, Makanji Y, Tanabe N, Yu DY, Tan JY, Lim S, Kouhkamari MH, Casorso J, Wu DB*, Bloomfield P. Comparative treatment persistence and adherence to endothelin receptor antagonists among patients with pulmonary arterial hypertension in Japan: A real-world administrative claims database study (*: Corresponding author). (2023) Pulmonary Therapy DOI: 10.1007/s41030-023-00244-w
• Chng WJ, Wu DB, Wu CKW, Springford A, Daly C, Jung SH. Bayesian matching adjusted indirect comparisons of daratumumab-pomalidomide-dexamethasone and pomalidomide-bortezomib-dexamethasone in relapsed/refractory multiple myeloma (RRMM). Clinical Lymphoma, Myeloma & Leukemia. 2025;S2152-2650(25)00069-2.